Latest & greatest articles for testosterone

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on testosterone or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on testosterone and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for testosterone

41. Is Testosterone Detrimental to Renal Function? Full Text available with Trip Pro

Is Testosterone Detrimental to Renal Function? 29318206 2019 02 26 2468-0249 1 4 2016 Nov Kidney international reports Kidney Int Rep Is Testosterone Detrimental to Renal Function? 306-310 10.1016/j.ekir.2016.07.004 Filler Guido G Department of Paediatrics, Children's Hospital at London Health Science Centre, London, Ontario, Canada. Department of Pathology and Laboratory Medicine, University of Western Ontario, London, Ontario, Canada. Department of Medicine, University of Western Ontario

2016 Kidney international reports

42. Testosterone Treatment in Older Men. (Abstract)

Testosterone Treatment in Older Men. 27406354 2016 07 14 2018 12 02 1533-4406 375 1 2016 07 07 The New England journal of medicine N. Engl. J. Med. Testosterone Treatment in Older Men. 90 10.1056/NEJMc1603665 Snyder Peter J PJ Ellenberg Susan S SS Farrar John T JT eng Letter Comment United States N Engl J Med 0255562 0028-4793 3XMK78S47O Testosterone AIM IM N Engl J Med. 2016 Feb 18;374(7):611-24 26886521 N Engl J Med. 2016 Jul 7;375(1):88 27406355 N Engl J Med. 2016 Jul 7;375(1):89-90 27406358 (...) N Engl J Med. 2016 Jul 7;375(1):88-9 27406356 N Engl J Med. 2016 Jul 7;375(1):89 27406357 Fatigue drug therapy Hormone Replacement Therapy Humans Male Sexual Behavior drug effects Testosterone therapeutic use Walking physiology 2016 7 14 6 0 2016 7 15 6 0 2016 7 15 6 1 ppublish 27406354 10.1056/NEJMc1603665 10.1056/NEJMc1603665#SA5

2016 NEJM

43. Testosterone Treatment in Older Men. Full Text available with Trip Pro

Testosterone Treatment in Older Men. 27406355 2016 07 14 2018 12 02 1533-4406 375 1 2016 07 07 The New England journal of medicine N. Engl. J. Med. Testosterone Treatment in Older Men. 88 10.1056/NEJMc1603665 Perls Thomas T TT Boston University School of Medicine, Boston, MA thperls@bu.edu. eng Letter Comment United States N Engl J Med 0255562 0028-4793 3XMK78S47O Testosterone AIM IM N Engl J Med. 2016 Feb 18;374(7):611-24 26886521 N Engl J Med. 2016 Jul 7;375(1):90 27406354 Fatigue drug (...) therapy Hormone Replacement Therapy Humans Male Sexual Behavior drug effects Testosterone therapeutic use Walking physiology 2016 7 14 6 0 2016 7 15 6 0 2016 7 15 6 1 ppublish 27406355 10.1056/NEJMc1603665 10.1056/NEJMc1603665#SA1

2016 NEJM

44. Testosterone Treatment in Older Men. Full Text available with Trip Pro

Testosterone Treatment in Older Men. 27406356 2016 07 14 2018 12 02 1533-4406 375 1 2016 07 07 The New England journal of medicine N. Engl. J. Med. Testosterone Treatment in Older Men. 88-9 10.1056/NEJMc1603665 Stavropoulos Konstantinos K Aristotle University of Thessaloniki, Thessaloniki, Greece kostasimprialos@hotmail.com. Boutari Chrysoula C Aristotle University of Thessaloniki, Thessaloniki, Greece kostasimprialos@hotmail.com. Imprialos Konstantinos K Aristotle University of Thessaloniki (...) , Thessaloniki, Greece kostasimprialos@hotmail.com. eng Letter Comment United States N Engl J Med 0255562 0028-4793 3XMK78S47O Testosterone AIM IM N Engl J Med. 2016 Feb 18;374(7):611-24 26886521 N Engl J Med. 2016 Jul 7;375(1):90 27406354 Fatigue drug therapy Hormone Replacement Therapy Humans Male Sexual Behavior drug effects Testosterone therapeutic use Walking physiology 2016 7 14 6 0 2016 7 15 6 0 2016 7 15 6 1 ppublish 27406356 10.1056/NEJMc1603665 10.1056/NEJMc1603665#SA2

2016 NEJM

45. Testosterone Treatment in Older Men. Full Text available with Trip Pro

Testosterone Treatment in Older Men. 27406357 2016 07 14 2018 12 02 1533-4406 375 1 2016 07 07 The New England journal of medicine N. Engl. J. Med. Testosterone Treatment in Older Men. 89 10.1056/NEJMc1603665 Mata Douglas A DA Brigham and Women's Hospital, Boston, MA dmata@bwh.harvard.edu. Ramasamy Ranjith R University of Miami Miller School of Medicine, Miami, FL. Lipshultz Larry I LI Baylor College of Medicine, Houston, TX. eng Letter Comment United States N Engl J Med 0255562 0028-4793 (...) 3XMK78S47O Testosterone AIM IM N Engl J Med. 2016 Feb 18;374(7):611-24 26886521 N Engl J Med. 2016 Jul 7;375(1):90 27406354 Fatigue drug therapy Hormone Replacement Therapy Humans Male Sexual Behavior drug effects Testosterone therapeutic use Walking physiology 2016 7 14 6 0 2016 7 15 6 0 2016 7 15 6 1 ppublish 27406357 10.1056/NEJMc1603665 10.1056/NEJMc1603665#SA3

2016 NEJM

46. Testosterone Treatment in Older Men. Full Text available with Trip Pro

Testosterone Treatment in Older Men. 27406358 2016 07 14 2018 12 02 1533-4406 375 1 2016 07 07 The New England journal of medicine N. Engl. J. Med. Testosterone Treatment in Older Men. 89-90 10.1056/NEJMc1603665 Laurent Michaël R MR KU Leuven, Leuven, Belgium dirk.vanderschueren@uzleuven.be. Antonio Leen L KU Leuven, Leuven, Belgium dirk.vanderschueren@uzleuven.be. Vanderschueren Dirk D KU Leuven, Leuven, Belgium dirk.vanderschueren@uzleuven.be. eng Letter Comment United States N Engl J Med (...) 0255562 0028-4793 3XMK78S47O Testosterone AIM IM N Engl J Med. 2016 Feb 18;374(7):611-24 26886521 N Engl J Med. 2016 Jul 7;375(1):90 27406354 Fatigue drug therapy Hormone Replacement Therapy Humans Male Sexual Behavior drug effects Testosterone therapeutic use Walking physiology 2016 7 14 6 0 2016 7 15 6 0 2016 7 15 6 1 ppublish 27406358 10.1056/NEJMc1603665 10.1056/NEJMc1603665#SA4

2016 NEJM

47. Establishing a Framework - Does Testosterone Supplementation Help Older Men? (Abstract)

Establishing a Framework - Does Testosterone Supplementation Help Older Men? 26886526 2016 03 02 2018 12 02 1533-4406 374 7 2016 Feb 18 The New England journal of medicine N. Engl. J. Med. Establishing a Framework--Does Testosterone Supplementation Help Older Men? 682-3 10.1056/NEJMe1600196 Orwoll Eric S ES From the Department of Medicine, Oregon Health and Science University, Portland. eng Editorial Comment United States N Engl J Med 0255562 0028-4793 3XMK78S47O Testosterone AIM IM N Engl J (...) Med. 2016 Feb 18;374(7):611-24 26886521 Fatigue drug therapy Hormone Replacement Therapy Humans Male Sexual Behavior drug effects Testosterone therapeutic use Walking physiology 2016 2 18 6 0 2016 2 18 6 0 2016 3 5 6 0 ppublish 26886526 10.1056/NEJMe1600196

2016 NEJM

48. It’s time to reconsider early-morning testosterone tests

It’s time to reconsider early-morning testosterone tests It's time to reconsider early-morning testosterone tests Toggle navigation Shared more. Cited more. Safe forever. Toggle navigation View Item JavaScript is disabled for your browser. Some features of this site may not work without it. Search MOspace This Collection Browse Statistics It's time to reconsider early-morning testosterone tests View/ Open Date 2015-07 Format Metadata Abstract Guidelines recommend collecting an early-morning (...) sample to compensate for the natural diurnal variation in testosterone levels. But for men 45 and older, this is unnecessary. Practice changer: Early-morning testosterone tests are necessary only for men younger than age 45. Because the natural diurnal variation in testosterone levels tends to diminish with age, it is acceptable to test men ages 45 and older before 2 pm.1 URI Part of Citation Journal of Family Practice, 64(7) 2015: 418-419. Rights OpenAccess. This work is licensed under a Creative

2016 PURLS

49. Endocrine Society of Australia position statement on male hypogonadism (part 1): assessment and indications for testosterone therapy

Endocrine Society of Australia position statement on male hypogonadism (part 1): assessment and indications for testosterone therapy Endocrine Society of Australia position statement on male hypogonadism (part 1): assessment and indications for testosterone therapy | The Medical Journal of Australia mja-search search Use the for more specific terms. Title contains Body contains Date range from Date range to Article type Author's surname Volume First page doi: 10.5694/mja__.______ Search Reset (...)  close Individual Login Purchase options Connect person_outline Login keyboard_arrow_down Individual Login Purchase options menu search Advertisement close Endocrine Society of Australia position statement on male hypogonadism (part 1): assessment and indications for testosterone therapy Bu B Yeap, Mathis Grossmann, Robert I McLachlan, David J Handelsman, Gary A Wittert, Ann J Conway, Bronwyn GA Stuckey, Douglas W Lording, Carolyn A Allan, Jeffrey D Zajac and Henry G Burger Med J Aust 2016; 205 (4

2016 MJA Clinical Guidelines

50. Diagnosis and management of testosterone deficiency syndrome in men: clinical practice guideline

Diagnosis and management of testosterone deficiency syndrome in men: clinical practice guideline Guidelines CMAJ ©2015 8872147 Canada Inc. or its licensors CMAJ 1 CME T estosterone deficiency syndrome, also known as late-onset hypogonadism, is a clinical and biochemical syndrome that can occur in men in association with advancing age. The condition is characterized by deficient testicular production of testosterone. It may affect multiple organ systems and can result in substantial health (...) consequences. 1 The management of testosterone deficiency syndrome in men is associated with much contro- versy, creating confusion and reluctance among health practitioners in dealing with the subject. A small number of professional bodies 2,3 have pub- lished guidelines on the topic, yet a multidisci- plinary guideline with specific Can adian content did not exist. This is relevant because there are important differences in health care systems com- pared with other jurisdictions in North America

2015 CPG Infobase

51. It’s time to reconsider early-morning testosterone tests

It’s time to reconsider early-morning testosterone tests It's time to reconsider early-morning testosterone tests Toggle navigation Shared more. Cited more. Safe forever. Toggle navigation View Item JavaScript is disabled for your browser. Some features of this site may not work without it. Search MOspace This Collection Browse Statistics It's time to reconsider early-morning testosterone tests View/ Open Date 2015-07 Format Metadata Abstract Guidelines recommend collecting an early-morning (...) sample to compensate for the natural diurnal variation in testosterone levels. But for men 45 and older, this is unnecessary. Practice changer: Early-morning testosterone tests are necessary only for men younger than age 45. Because the natural diurnal variation in testosterone levels tends to diminish with age, it is acceptable to test men ages 45 and older before 2 pm.1 URI Part of Citation Journal of Family Practice, 64(7) 2015: 418-419. Rights OpenAccess. This work is licensed under a Creative

2015 PURLS

52. Testosterone and "Age-Related Hypogonadism" - FDA Concerns. (Abstract)

Testosterone and "Age-Related Hypogonadism" - FDA Concerns. 26287846 2015 08 25 2016 11 25 1533-4406 373 8 2015 Aug 20 The New England journal of medicine N. Engl. J. Med. Testosterone and "Age-Related Hypogonadism"--FDA Concerns. 689-91 10.1056/NEJMp1506632 Nguyen Christine P CP From the Food and Drug Administration, Silver Spring, MD. Hirsch Mark S MS Moeny David D Kaul Suresh S Mohamoud Mohamed M Joffe Hylton V HV eng Journal Article United States N Engl J Med 0255562 0028-4793 3XMK78S47O (...) Testosterone AIM IM Advertising as Topic Age Factors Aged Cardiovascular Diseases chemically induced Drug Industry Drug Labeling legislation & jurisprudence Government Regulation Humans Hypogonadism drug therapy Male Middle Aged National Academies of Science, Engineering, and Medicine (U.S.) Health and Medicine Division Off-Label Use Testosterone adverse effects blood therapeutic use United States United States Food and Drug Administration 2015 8 20 6 0 2015 8 20 6 0 2015 8 26 6 0 ppublish 26287846 10.1056

2015 NEJM

53. Effects of Testosterone Administration for 3 Years on Subclinical Atherosclerosis Progression in Older Men With Low or Low-Normal Testosterone Levels: A Randomized Clinical Trial. Full Text available with Trip Pro

Effects of Testosterone Administration for 3 Years on Subclinical Atherosclerosis Progression in Older Men With Low or Low-Normal Testosterone Levels: A Randomized Clinical Trial. Testosterone use in older men is increasing, but its long-term effects on progression of atherosclerosis are unknown.To determine the effect of testosterone administration on subclinical atherosclerosis progression in older men with low or low-normal testosterone levels.Testosterone's Effects on Atherosclerosis (...) Progression in Aging Men (TEAAM) was a placebo-controlled, double-blind, parallel-group randomized trial involving 308 men 60 years or older with low or low-normal testosterone levels (100-400 ng/dL; free testosterone <50 pg/mL), recruited at 3 US centers. Recruitment took place between September 2004 and February 2009; the last participant completed the study in May 2012.One hundred fifty-six participants were randomized to receive 7.5 g of 1% testosterone and 152 were randomized to receive placebo gel

2015 JAMA Controlled trial quality: predicted high

54. Comparative Safety of Testosterone Dosage Forms Full Text available with Trip Pro

Comparative Safety of Testosterone Dosage Forms Increases in testosterone use and mixed reports of adverse events have raised concerns about the cardiovascular safety of testosterone. Testosterone is available in several delivery mechanisms with varying pharmacokinetics; injections cause spikes in testosterone levels, and transdermal patches and gels cause more subtle but sustained increases. The comparative cardiovascular safety of gels, injections, and patches has not been studied.To (...) determine the comparative cardiovascular safety of testosterone injections, patches, and gels.A retrospective cohort study was conducted using administrative claims from a commercially insured (January 1, 2000, to December 31, 2012) and Medicare (January 1, 2007, to December 31, 2010) population in the United States and general practitioner records from the United Kingdom (January 1, 2000, to June 30, 2012). Participants included men (aged ≥18 years) who initiated use of testosterone patches, gels

2015 EvidenceUpdates

55. Testosterone in Men with Erectile Dysfunction with No Symptoms of Hypogonadism

Testosterone in Men with Erectile Dysfunction with No Symptoms of Hypogonadism Disclaimer: The Rapid Response Service is an information service for those involved in planning and providing health care in Canada. Rapid responses are based on a limited literature search and are not comprehensive, systematic reviews. The intent is to provide a list of sources of the best evidence on the topic that CADTH could identify using all reasonable efforts within the time allowed. Rapid responses should (...) study only. It may not be copied, posted on a web site, redistributed by email or stored on an electronic system without the prior written permission of CADTH or applicable copyright owner. Links: This report may contain links to other information available on the websites of third parties on the Internet. CADTH does not have control over the content of such sites. Use of third party sites is governed by the owners’ own terms and conditions. TITLE: Testosterone in Men with Erectile Dysfunction

2015 Canadian Agency for Drugs and Technologies in Health - Rapid Review

56. Testosterone and Cardiovascular Health: Safety of Treatment of Hypogonadism. (Abstract)

Testosterone and Cardiovascular Health: Safety of Treatment of Hypogonadism. Controversy has arisen over the issue of the cardiovascular safety of testosterone.The aim of this article is to examine the evidence as to the cardiovascular safety involved with the administration of testosterone.A literature review was performed with regard to cardiovascular safety of testosterone.The main outcome measure was to evaluate the available evidence as to cardiovascular safety and risk of testosterone.A (...) handful of recently published and widely discussed manuscripts have suggested that administration of testosterone replacement therapy increases the frequency of adverse cardiovascular events. In contrast, there have been recent clinical reports suggesting that testosterone is either safe or actually reduces cardiovascular events and mortality. All of these studies-both those suggesting that testosterone has adverse effects, as well as those suggesting it has positive effects on the cardiovascular

2015 Sexual medicine reviews Controlled trial quality: predicted high

57. Testosterone testing

Testosterone testing Final Testosterone Testing: Findings & Decision Page 1 of 3 Health Technology Clinical Committee Final Findings and Decision Topic: Testosterone Testing Meeting Date: March 20, 2015 Final Adoption: May 15, 2015 Meeting materials and transcript are available on the HTA website: www.hca.wa.gov/hta/meetingmaterials/Forms/ExtMeetingMaterials.aspx Number and Coverage Topic: 20150320A – Testosterone Testing HTCC Coverage Determination: Testosterone testing is a covered benefit (...) of testosterone therapy Non-covered Indicators: N/A This decision does not apply to females, males under age 18, or transgender persons. Agency Contact Information: Agency Phone Number Labor and Industries 1-800-547-8367 Public Employees Health Plan 1-800-200-1004 Washington State Medicaid 1-800-562-3022 WA - Health Technology Assessment March 20, 2015 Final Testosterone Testing: Findings & Decision Page 2 of 3 HTCC Coverage Vote and Formal Action Committee Decision Based on the deliberations of key health

2015 Washington Health Care Authority

58. Effect of Testosterone Treatment on Glucose Metabolism in men With Type 2 Diabetes: A Randomized Controlled Trial Full Text available with Trip Pro

Effect of Testosterone Treatment on Glucose Metabolism in men With Type 2 Diabetes: A Randomized Controlled Trial To determine whether testosterone therapy improves glucose metabolism in men with type 2 diabetes (T2D) and lowered testosterone.We conducted a randomized, double-blind, parallel, placebo-controlled trial in 88 men with T2D, aged 35-70 years with an HbA1c ≤8.5% (69 mmol/mol), and a total testosterone level, measured by immunoassay, of ≤12.0 nmol/L (346 ng/dL). Participants were (...) randomly assigned to 40 weeks of intramuscular testosterone undecanoate (n = 45) or matching placebo (n = 43). All study subjects were included in the primary analysis. Seven men assigned to testosterone and six men receiving placebo did not complete the study. Main outcome measures were insulin resistance by homeostatic model assessment (HOMA-IR, primary outcome) and glycemic control by HbA1c (secondary outcome).Testosterone therapy did not improve insulin resistance (mean adjusted difference [MAD

2014 EvidenceUpdates Controlled trial quality: predicted high

59. Testosterone Therapy and Risk of Recurrence After Treatment for Prostate Cancer

Testosterone Therapy and Risk of Recurrence After Treatment for Prostate Cancer Testosterone Therapy and Risk of Recurrence After Treatment for Prostate Cancer Toggle navigation Shared more. Cited more. Safe forever. Toggle navigation View Item JavaScript is disabled for your browser. Some features of this site may not work without it. Search MOspace This Collection Browse Statistics Testosterone Therapy and Risk of Recurrence After Treatment for Prostate Cancer View/ Open Date 2013-10 Format (...) Metadata Abstract Evidence-Based Answer: Men with symptomatic androgen deprivation who have had clinically curative treatment for organ-confined prostate cancer may have symptomatic improvement with testosterone replacement therapy. (Strength of Recommendation [SOR]: C, based on two small case series.) There are no studies evaluating the risk of cancer recurrence in patients receiving testosterone replacement therapy. However, testosterone replacement therapy may be associated with increased prostate

2014 Clinical Inquiries

60. Natesto (testosterone) Nasal Gel

Natesto (testosterone) Nasal Gel Drug Approval Package: Brand Name (Generic Name) NDA # Drug Approval Package U.S. Food & Drug Administration Search FDA Drug Approval Package - Natesto (testosterone) Nasal Gel Company: Trimel Biopharma, Inc. Application No.: 205488 Approval Date: 5/28/2014 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) Date created

2014 FDA - Drug Approval Package